Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.60 |
| ▸ | FNTB | P49356 | 10/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 10/20 | 0.60 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20540520 | 1.00 | FNTA (0.60) | FNTAFNTBPGGT1BMMEALDH1A1 | |
| SCHEMBL7609991 | 0.89 | NPY1R (0.53) | FNTAFNTBPGGT1BMME | |
| SCHEMBL7609995 | 0.89 | NPY1R (0.53) | FNTAFNTBPGGT1BMME | |
| SCHEMBL13154780 | 0.89 | FNTA (0.60) | FNTAFNTBPGGT1BMMELTA4H | |
| SCHEMBL9442969 | 0.89 | FNTA (0.60) | FNTAFNTBPGGT1BMMELTA4H | |
| SCHEMBL10696437 | 0.89 | FNTA (0.60) | FNTAFNTBPGGT1BMMELTA4H | |
| SCHEMBL9442973 | 0.89 | FNTA (0.60) | FNTAFNTBPGGT1BMMELTA4H | |
| SCHEMBL20540710 | 0.87 | FNTA (0.48) | FNTAFNTBPGGT1BMMELTA4H | |
| SCHEMBL22503733 | 0.87 | FNTA (0.57) | FNTAFNTBPGGT1BALDH1A1 | |
| SCHEMBL20540709 | 0.87 | FNTA (0.48) | FNTAFNTBPGGT1BMMELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453699-B2 | Antimicrobial compounds and/or modulators of microbial infections and methods of using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-09-27 | — | — | US | disclosed |
| US-20210054025-A1 | ANTIMICROBIAL COMPOUNDS AND/OR MODULATORS OF MICROBIAL INFECTIONS AND METHODS OF USING THE SAME | UNIV INDIANA RES & TECH CORP (US) | 2021-02-25 | — | — | US | disclosed |
| US-10793594-B2 | Antimicrobial compounds and/or modulators of microbial infections and methods of using the same | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180305402-A1 | ANTIMICROBIAL COMPOUNDS AND/OR MODULATORS OF MICROBIAL INFECTIONS AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793594-B2 | Antimicrobial compounds and/or modulators of microbial infections and methods of using the same | CD47, CGAS, FPR1 | FNTA 439/4885FNTB 472/4885PGGT1B 827/4885 |
| US-20180305402-A1 | ANTIMICROBIAL COMPOUNDS AND/OR MODULATORS OF MICROBIAL INFECTIONS AND METHODS OF USING THE SAME | CD47, CGAS, FPR1 | FNTA 439/4885FNTB 472/4885PGGT1B 827/4885 |
| US-11453699-B2 | Antimicrobial compounds and/or modulators of microbial infections and methods of using the same | CD47, CGAS, FPR1 | FNTA 439/4885FNTB 472/4885PGGT1B 827/4885 |
| US-20210054025-A1 | ANTIMICROBIAL COMPOUNDS AND/OR MODULATORS OF MICROBIAL INFECTIONS AND METHODS OF USING THE SAME | CD47, CGAS, FPR1 | FNTA 439/4885FNTB 472/4885PGGT1B 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.